Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors.
about
Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancerDNA-repair pathway inhibitors for the treatment of ovarian cancerPoly(ADP-ribose)-dependent regulation of Snail1 protein stabilityNuclear ADP-ribosylation reactions in mammalian cells: where are we today and where are we going?Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian CancerThe Role of Poly(ADP-ribose) Polymerase-1 in Rheumatoid ArthritisPARPs and the DNA damage responseThe role of PARP in DNA repair and its therapeutic exploitationOverview of base excision repair biochemistryJNK signalling in cancer: in need of new, smarter therapeutic targetsPARP inhibition in leukocytes diminishes inflammation via effects on integrins/cytoskeleton and protects the blood-brain barrier.Neuronal death induced by misfolded prion protein is due to NAD+ depletion and can be relieved in vitro and in vivo by NAD+ replenishment.PARP1 gene knock-out increases resistance to retinal degeneration without affecting retinal function.A third zinc-binding domain of human poly(ADP-ribose) polymerase-1 coordinates DNA-dependent enzyme activationStructure of mouse ADP-ribosylhydrolase 3 (mARH3)Recognition of the iso-ADP-ribose moiety in poly(ADP-ribose) by WWE domains suggests a general mechanism for poly(ADP-ribosyl)ation-dependent ubiquitinationFamily-wide chemical profiling and structural analysis of PARP and tankyrase inhibitorsPoly(ADP-ribose) polymerase inhibition reveals a potential mechanism to promote neuroprotection and treat neuropathic painPathophysiological Role of Peroxynitrite Induced DNA Damage in Human Diseases: A Special Focus on Poly(ADP-ribose) Polymerase (PARP)Computer-aided Molecular Design of Compounds Targeting Histone Modifying EnzymesNAD metabolism and sirtuins: metabolic regulation of protein deacetylation in stress and toxicityModeling pharmacodynamic response to the poly(ADP-Ribose) polymerase inhibitor ABT-888 in human peripheral blood mononuclear cellsInhibition of poly(ADP-ribose) polymerase interferes with Trypanosoma cruzi infection and proliferation of the parasiteTime-Dependent and Organ-Specific Changes in Mitochondrial Function, Mitochondrial DNA Integrity, Oxidative Stress and Mononuclear Cell Infiltration in a Mouse Model of Burn InjuryPeroxynitrite inhibits myofibrillar protein function in an in vitro assay of motilityMechanisms of ascorbate-induced cytotoxicity in pancreatic cancerModulation of epigenetic targets for anticancer therapy: clinicopathological relevance, structural data and drug discovery perspectivesSingle cell resolution in vivo imaging of DNA damage following PARP inhibitionUninephrectomized High-Fat-Fed Nicotinamide-Streptozotocin-Induced Diabetic Rats: A Model for the Investigation of Diabetic Nephropathy in Type 2 Diabetes.Autophagy Protects from Raddeanin A-Induced Apoptosis in SGC-7901 Human Gastric Cancer Cells.Synthesis, [¹⁸F] radiolabeling, and evaluation of poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors for in vivo imaging of PARP-1 using positron emission tomography.A selective eradication of human nonhereditary breast cancer cells by phenanthridine-derived polyADP-ribose polymerase inhibitorsStrategies for the Use of Poly(adenosine diphosphate ribose) Polymerase (PARP) Inhibitors in Cancer Therapy.Functional Aspects of PARP1 in DNA Repair and Transcription.A rapid and sensitive method for determination of veliparib (ABT-888), in human plasma, bone marrow cells and supernatant by using LC/MS/MS.Poly(ADP-ribose) polymerase inhibitors in triple-negative breast cancer.Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699.Supraspinal inactivation of mitochondrial superoxide dismutase is a source of peroxynitrite in the development of morphine antinociceptive tolerance.Radiosensitivity and Induction of Apoptosis by High LET Carbon Ion Beam and Low LET Gamma Radiation: A Comparative Study.New therapeutic and biomarker discovery for peripheral diabetic neuropathy: PARP inhibitor, nitrotyrosine, and tumor necrosis factor-{alpha}
P2860
Q24187899-E2FC1B26-20B4-4BB9-BB2D-8F9B259B4C0DQ24234893-8A0F922A-AEB3-4A1A-97B5-FE1782A288E1Q24303474-912CD512-9274-4EDD-9D77-5D6E0B168DE6Q24669960-FF1565BA-11BB-4B06-905C-4E89604DECA8Q26783551-485B6435-1E34-4E80-9CE5-992933D3674AQ26785513-0A113303-934B-4861-81C8-7BF0A17FA18DQ26859010-E27FF723-C997-41D1-9405-87FDEF03C086Q27002399-41506EB6-A1A7-4A45-9D8A-8E5D81BD8BA8Q27021659-EC41EA62-6DB5-4F02-A695-C767362957F1Q27023869-5090EEA7-A95A-4050-B050-862AEDEF259BQ27303034-22CB8BE6-7828-4512-B125-0DAE59F17FC7Q27303843-E8CEC455-41FD-4E10-952A-909D393709A9Q27312275-D2C73F8B-2CF7-48B3-B436-29AA4D992674Q27649201-314590BA-999A-4494-B787-CC00874215BDQ27650003-FEB0E37B-54F5-45EF-A061-55B7D2F6C9F6Q27676844-F6731987-74EA-405B-9431-D833E7759EE0Q27677345-003F33AE-6395-437E-8B73-147EA70263BCQ28073384-1C7723F2-A386-4E75-A2E3-A71489B3AB4CQ28080057-4AFDDE02-3F53-45CB-87A1-21F1B1403271Q28083849-B174FED4-9C7C-4DE7-96AD-FC3168B2C51CQ28476267-45331D6D-AD3E-4A14-AAD0-B4D020DD85E8Q28477427-383663F0-6D4D-4A84-B39E-1E97BAB9B8B3Q28483989-A7238774-43FE-44EE-B103-664F404B3F9AQ28551267-A637371B-952E-47E0-80C2-D18FF8BBAF1DQ30443968-FF3E1254-D2BD-4B13-9E1C-09078FA9A177Q30492805-F1D908B7-95A2-451A-AC41-D91D292917C8Q30570945-A7476B76-6FD1-4001-BF36-417CA37B1A75Q30650918-4FF26D0B-EAAF-418B-B4E3-74AD221D6980Q30833537-86326927-5ED7-473A-8148-66DF37D463EAQ32183889-E32BC5FD-5B42-4BEB-BBA6-71E27602EE6CQ33607384-5A1C7065-ADFC-4C27-9B9A-16629FA7EB53Q33627135-0503E3B6-BD0E-4568-9A8A-DDB49565A057Q33649555-CD1F912F-119A-4998-B420-0CAA861A00E3Q33649584-3E31ADE1-7301-4BEE-A1EC-849D3C458167Q33654889-A4C859C0-4E3A-436D-9966-8935C4FB292EQ33669053-E58469FF-9369-4388-B760-DDCF4E7C25C9Q33729396-817888E1-8971-482A-B7D2-D190A6E38959Q33813707-AD8D212A-F3B1-4A66-94CC-C1B37B56F980Q33853026-B2FD3FE3-190A-4625-8482-71A53D5FFD82Q33874485-B8A96DAA-7321-4F26-B837-46C9A181EA71
P2860
Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors.
@ast
Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors.
@en
type
label
Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors.
@ast
Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors.
@en
prefLabel
Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors.
@ast
Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors.
@en
P2860
P356
P1476
Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors.
@en
P2093
Csaba Szabó
Prakash Jagtap
P2860
P2888
P304
P356
10.1038/NRD1718
P577
2005-05-01T00:00:00Z